Skip to main content

Table 3 HBsAg antibody responses

From: IMP321 (sLAG-3), an immunopotentiator for T cell responses against a HBsAg antigen in healthy adults: a single blind randomised controlled phase I study

Engerix® -B     HBsAg + IMP321 10 μg    
Subject W0 W8 W12 Subject W0 W8 W12
003 0 178 2253 013 0 0 1
008 0 2589 7055 015 0 0 4
014 0 0 54 017 0 0 0
023 0 4 442 018 0 2 28
026 0 3054 3156 019 9 504 609
032 0 0 28 020 0 0 0
040 0 9 164 1021 0 0 0
043 0 2 17 022 0 0 0
# Seroconverteda 0 6 (75%) 8 (100%) # Seroconverteda 0 1 (14.2%) 3 (42.8%)
# Seroprotecteda 0 3 (37.5%) 8 (100%) # Seroprotecteda 0 0 1 (14.2%)
GMTa, b 1 23.75 313.56 GMTa, b 1 1.10 1.96
HBsAg alone     HBsAg + IMP321 30 μg    
006 0 0 0 025 0 0 0
012 0 0 0 027 0 0 0
016 0 0 0 029 0 0 0
024 0 0 0 030 0 0 26
028 0 0 7 031 0 0 0
034 0 0 0 033 0 0 4
039 0 0 2 035 2 136 467
044 1 24 321 036 0 0 0
# Seroconverteda 0 0 2 (28.5%) # Seroconverteda 0 0 2 (28.5%)
# Seroprotecteda 0 0 0 # Seroprotecteda 0 0 1 (14.2%)
GMTa, b 1 1 1.46 GMTa, b 1 1 1.94
HBsAg + IMP321 3 μg     HBsAg + IMP321 100 μg    
001 0 540 2229 037 0 0 3
002 0 35 51 038 0 0 3
004 0 0 0 041 0 0 0
005 0 0 0 042 0 0 0
007 0 0 1 045 0 0 0
009 0 0 12 046 0 0 0
1010 0 0 1 047 0 0 0
011 0 0 5 048 0 0 0
# Seroconverteda 0 2 (25%) 6 (75%) # Seroconverteda 0 0 2 (25%)
# Seroprotecteda 0 2 (25%) 3 (37.5%) # Seroprotecteda 0 0 0
GMTa, b 1 3.42 7.15 GMTa, b 1 1 1.31
  1. Protective titres are indicated in bold
  2. a GMT, seroconversion and seroprotection calculations were based on naïve subjects only.
  3. b Value of zero are assigned the value of 1 for the GMT calculation.
Back to article page

Journal of Immune Based Therapies and Vaccines

ISSN: 1476-8518

\